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INTRODUCTION
Ovarian cancer is the fifth leading cause of death
worldwide and is the most deadly cancer among
all gynecology cancer. Annually, there are 204.000
women diagnosed with ovarian cancer, and
125.000 women died of the disease worldwide.1
The risk of ovarian cancer occurrence in women
is 1 : 70, and is related to the age of the patients,
which is approximately 61 years old. Eighty-five to
ninety percent of diagnosed ovarian cancer is
known as the epithelial type of ovarian cancer.
Hereditary factor is the major risk factor for the
disease, especially the presence of ovarian cancer
history in the family. Approximately 5-10% of
ovarian cancer cases were suspected inherited,
while the remaining 90-95% are related to
continuous ovulation cycle.1
Ovarian cancer is a very challenging clinical
situation because initially, the disease does not
provoke any symptom. Thus, more than two-third
Abstract
Objective: To address the endoglin expression (CD105) in the
primary tumour and metastases tumour (omentum) and their
relat ion with  c l inicopathological  factors:  stadium,
differentiation level, and histological epithelial ovarian cancer.
Methods: The research was performed at Public Service Hall of
Dr. Wahidin Sudirohusodo Hospital and educational networking
hospital of Obstetrics and Gynecology Department of Faculty of
Medicine Universitas Hasanuddin. The research design is cross-
sectional with 55 samples consisting of 55 samples of primary
tumours and 55 metastatic tumours. Imunohistochemistry
examination was performed on all samples.
Results: The results show a significant relation between endoglin
(CD105) at omentum metastases tumour and stadium and cell
differentiation level of epithelial ovarian cancer. There is no
significant relation between endoglin (CD105) expression at
primary tumour of ovarian cancer and stadium and differentiation
and type of histopathological cell. In addition, there is no signifi-
cant relation between endoglin expression (CD105) in omentum
metastases tumour and type of histopathological cell of ovarian
cancer. There is a significant correlation (strong category)
between endoglin expression at omentum metastases tumour
and endoglin expression at primary tumour of epithelial
ovarian cancer.
Conclusion: Endoglin expression in ovarian cancer metastatic
tumour to omentum is correlated with clinical stage and
differentiation level of ovarian cancer. And endoglin is one
of the proangiogenic and prometastatic factors.
[Indones J Obstet Gynecol 2018; 6-2: 123-129]
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Abstrak
Tujuan: Mengetahui ekspresi endoglin (CD105) pada tumor primer
dan tumor metastases (omentum) serta hubungannya dengan faktorklinikopatologik: stadium, derajat diferensiasi, dan jenis histopatologi
kanker ovarium tipe epitel.
Metode: Penelitian ini menggunakan rancangan potong lintang.
Penelitian dilaksanakan di BLU RS Dr. Wahidin Sudirohusodo dan RS
jejaring pendidikan Departemen Obstetri dan Ginekologi FakultasKedokteran Universitas Hasanuddin Makassar. Sampel penelitian
sebanyak 55 orang dengan rincian masing-masing 55 sampel untukkelompok tumor primer dan 55 kelompok tumor metastases
omentum. Pemeriksaan imunohistokimia dilakukan terhadap semua
sampel.
Hasil: Hasil penelitian menunjukkan terdapat hubungan bermakna
antara ekspresi endoglin (CD105) pada tumor metastases omentumdengan stadium dan derajat diferensiasi sel kanker ovarium epitelial.
Tidak didapatkan hubungan bermakna antara ekspresi endoglin(CD105) pada tumor primer kanker ovarium dengan stadium, derajat
diferensiasi dan jenis histopatologi sel. Juga tidak didapatkan
hubungan bermakna antara ekspresi endogin (CD105) pada tumormetastases omentum dengan tipe histopatologi sel kanker ovarium.
Terdapat korelasi yang signifikan (kategori kuat) antara ekspresi
endoglin pada tumor metastases omentum dan ekspresi endoglinpada tumor primer kanker ovarium tipe epitelial.
Kesimpulan: Ekspresi endoglin pada tumor metastases omentum
kanker ovarium berhubungan dengan stadium klinis dan derajat
diferensiasi sel pada kasus kanker ovarium. Selain itu, endoglin jugamerupakan faktor proangiogenik dan prometastases.
[Maj Obstet Ginekol Indones 2018; 6-2: 123-129]
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of the cases are diagnosed in its late stage, where
cancer has been spread outside the ovary or even
widely metastasized.2 Although nowadays, the
aetiology of the disease is better understood, the
presence of aggressive cytoreductive surgery and
more combined modern chemotherapy, there is no
significant statistical mortality rate decrease in
the last 30 years.
In the last few years, the understanding of
molecular biology, especially regarding angio-
genesis in ovarian cancer, is improving, leading
to the finding of some new therapeutic target and
molecular prognostic factor. Hence, this triggers
the development of some more radical therapy of
ovarian cancer. Some factors that involve in angio-
genesis are keys to better understand the mecha-
nism and management of ovarian cancer. One of
the factors is Endoglin (CD105).
Endoglin (CD105) is the glycoprotein membrane
which is included in zona pellucida protein group.
Endoglin is expressed strongly in proliferated
vascular endothelial cells and has been identified
as an accessory receptor for transforming growth
factor- (TGF-). The endoglin gene in human is
located on chromosome 9q34ter.3
The main role of endoglin is regulating the
TGF--dependent vascular remodelling and
angiogenesis. The signal produced by the TGF-
might induce various process, including proli-
feration, migration, and adhesion. TGF- is
expressed in endothelial cells of the embryo,
infected tissue, healing tissue, inflamed arthritis
synovial, and solid tumour. Currently, endoglin is
suggested as the marker of neovascularization in
solid tumours.4
In the studies of fertility, endocrinology, and
reproduction, especially endometriosis, the role of
endoglin has been improved, compared with its
role in the cases of ovarian malignancies. The
serum endoglin level was identified as a predictor
factor of endometriosis, with the threshold of  11
ng/ml for endometriosis cases and <11 ng/ml for
non-endometriosis cases.5
The role of endoglin in the spreading process of
cancer has been discussed in several previous
studies. In the study of gastric cancer, found a
correlation of increased VEGF with endoglin
expression in tumours metastasized to the lymph
node, and suggested it as an important prognostic
indicator. Similar result was found by, indicated a
correlation of VEGF and endoglin expression in the
cases of prostate cancer, and suggested that the
increase of both VEGF and endoglin expression is
associated with the low survival rate. In breast
cancer, endoglin assessment has a higher speci-
ficity to assess the neovascularization compared
with other pan-endothelial markers, such as CD31,
CD34, and Von Willebrand Factor (vWF).6,7
The suppression of endoglin regulation may
trigger apoptosis, induce significant DNA destruc-
tion by modulating some DNA restoration gene,
increase the sensitivity of platinum, both in vivo
and in vitro, and become a specific therapeutic
target in epithelial ovarian cancer.8
Endoglin expression is frequently found in ova-
rian cancer effusion, both in the tumour cells and
the reactive mesothelial cells. The extent of endo-
glin expression is correlated to the chemotherapy
state, and endoglin expression is found higher in
solid metastatic tumour than that in effusion.9
The role of endoglin in ovarian cancer has not
been reported in a considerable number compared
with that in other malignancies, such as gastric
cancer, prostate cancer, and breast cancer. There-
fore, the investigators sensed the need to conduct
the study, which aims to understand the expres-
sion of endoglin (CD105) in primary and metastatic
tumours (omentum) as well as its correlation with
tumour clinicopathologic factors: staging, differen-
tiation level, and histopathology of epithelial ova-
rian cancer.
METHOD
Study Location and Period
The study was conducted in several educational
networking hospitals of Obstetrics and Gynecology
Department of the faculty of medicine of Univer-
sitas Hasanuddin: RS Dr. Wahidin Sudirohusodo,
RS Pendidikan UNHAS, RS Pelamonia, RSU Labuang
Baji, RSI Faisal, RS Bhayangkara, RS Ibnu Sina, and
RSUD Syekh Yusuf Gowa; as well as Pathology
Laboratory of Pathology Anatomy Department of
the faculty of medicine of Universitas Hasanuddin
and Pathology Laboratory of RS Dr. Wahidin
Sudirohusodo Makassar. The study was conducted
after been approved by the local authorities and
the patients in regard to the sampling process. The
study was conducted from December 2015 until
the period of the sample completion.
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Study Design and Variables
The study used cross-sectional study design. The
variables of the study consisted of: independent
variable (endoglin expression), dependent variable
(staging, differentiation level, histopathology of
epithelial ovarian cancer), intervening variable
(apoptosis inhibition, vasopermeability increase,
proliferation, migration, and invasion), and con-
founding variable (hereditary factor, hormonal
factor, radiation, and carcinogenic agents).
Population and Sample
The population of this study included all patients
with epithelial ovarian cancer who were treated
and underwent the surgery in RS Dr. Wahidin
Sudirohusodo Makassar and several educational
networking hospitals of Obstetrics and Gynecology
Department of the faculty of medicine of Univer-
sitas Hasanuddin Makassar. Sample is the part of
population. The sample of this study included all
patients with epithelial ovarian cancer who were
treated and underwent the surgery in RS Dr.
Wahidin Sudirohusodo Makassar and several
educational networking hospitals of Obstetrics and
Gynecology Department of the faculty of medicine
of Universitas Hasanuddin Makassar.
Data Collection Method
Patients who consented to participate in the study
should sign the informed consent form then
complete the questionnaire, consisted of history
taking, physical examination, and another workup.
The data were subsequently analyzed.
Data Analysis Technique
The data were categorised based on the purpose
and type of the data, with appropriate statistic
method, then processed with SPSS programme
for Windows version 16.
RESULT
The study was an observational study with a cross-
sectional design. This study aims to address
endoglin (CD105) expression in primary tumour
and metastatic tumour (omentum) of epithelial
ovarian cancer and its correlation with some
clinicopathology factors, such as clinical stage,
differentiation level, and histopathology type.
This study was conducted in several educational
hospitals of obstetrics and gynecology department
of faculty of medicine, Universitas Hasanuddin,
Makassar, from December 2015 until the period of
the sample completion.
There were 55 patients enrolled in the study
(20-76 years old) where most cases, as much as 27
(49.1%), were younger than 45 years old. As many
as 42 patients (76.4%) were unemployed. The
highest parity was 1-3 parities, which was found
in 23 patients (41.9%). Of all patients, 18 patients
(32.7%) suffered from early-stage ovarian cancer,
and 37 patients (67.3%) suffered from late-stage
ovarian cancer. Serous type of ovarian cancer was
found in 29 patients (52.7%), and mucinous type
was found in 26 patients (47.3%). Poorly differen-
tiated cell was found in 39 patients (70.9%), and
well differentiated cell was found in 16 patients
(29.1%) (Table 1).
Table 1. Characteristic of Sample
Characteristic
Total
n = 55 %
Age (year)
<45 27 49.1
45-50 20 36.4
>50 8 14.5
Parity
0 19 34.5
1-3 23 41.9
>3 13 23.6
Educational level
Uneducated 6 10.9
 9 years of education 32 58.2
> 9 years of education 17 30.9
Employment
Unemployment 42 76.4
Employment 13 23.6
Clinical stage
Early stage (I and II) 18 32.7
Late stage (III and IV) 37 67.3
Endoglin Expression (Primary)
Negative 10 18.2
Positive 45 81.8
Endoglin Expression (Omentum)
Negative 18 32.7
Positive 37 67.3
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The distribution of endoglin expression based
on the clinical stage in epithelial ovarian cancer
tissue (primary tumor) showed that both negative
endoglin expression and positive endoglin
expression (the weak and the strong one) were
found higher in late stage ovarian cancer, as much
as 60.0% and 68.9%, respectively. The distribution
of endoglin expression based on cell differentiation
of epithelial ovarian cancer (primary tumour)
showed that both negative and positive endoglin
expression in the primary tumour of ovarian
cancer was found higher in poorly differentiated
cell, as much as 70% and 71.1%, respectively. The
distribution of endoglin expression based on
histopathology type of epithelial ovarian cancer
(primary tumour) showed that both negative and
positive endoglin expression in the primary
tumour of ovarian cancer was found higher in
serous type, as much as 60.0% and 51.1%,
respectively. (Table 2).
The distribution of endoglin expression based
on the clinical stage of epithelial ovarian cancer
(omentum metastatic tumour) showed that
negative endoglin expression was found higher in
early-stage ovarian cancer (61.1%), while positive
endoglin expression was found higher in late stage
ovarian cancer (81.1%). The distribution of
endoglin expression based on cell differentiation of
epithelial ovarian cancer (omentum metastatic
tumour) showed that negative endoglin expression
was found higher in the well differentiated cell
(61.1%), while positive endoglin expression was
found higher in the poorly differentiated cell
(86.5%). The distribution of endoglin expression
based on histopathology type of epithelial ovarian
cancer (omentum metastatic tumour) showed that
negative endoglin expression was found higher
in serous type (61.1%), while positive endoglin
expression was found higher in mucinous type
(51.4%). (Table 3).
Table 2. Distribution of Endoglin Expression based on Clinical Stage, Cell Differentiation, and Histopathology Type
in Epithelial Ovarian Cancer Tissue (Primary Tumour)
Endoglin
Expression
Clinical Stage Cell Differentiation Histopathology Type
Early Late Total p Well Poor Total p Mucinous Serous Total p
n % n % n % n % n % n % n % n % n %
Negative  4 40.0  6 60.0 10 100.0  3 30.0  7 70.0 10 100.0  4 40.0  6 60.0 10 100.0
Positive 14 31.1 31 68.9 45 100.0 0.588 13 28.9 32 71.1 45 100.0 0.944 22 48.9 23 51.1 45 100.0 0.611
Total 18 32.7 37 67.3 55 100.0 16 29.1 39 70.9 55 100.0 26 47.3 29 52.7 55 100.0
Table 3. Distribution of Endoglin Expression based on Clinical Stage, Cell Differentiation, and Histopathology Type
in Epithelial Ovarian Cancer Tissue (Omentum Metastatic Tumour)
Endoglin
Expression
Clinical Stage Cell Differentiation Histopathology Type
Early Late Total p Well Poor Total p Mucinous Serous Total p
n % n % n % n % n % n % n % n % n %
Negative 11 61.1  7 38.9 18 100.0 11 61.1  7 38.9 18 100.0  7 38.9 11 61.1 18 100.0
Positive  7 18.9 30 81.1 37 100.0 0.002  5 13.5 32 86.5 37 100.0 0.000 19 51.4 18 48.6 37 100.0 0.385
Total 18 32.1 37 67.9 45 100.0 16 29.1 39 70.9 55 100.0 26 47.3 29 52.7 55 100.0
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There is a significant correlation of endoglin
expression in primary tumour and endoglin
expression in omentum metastatic tumour of
ovarian cancer (p<0.05). The coefficient value of
0.771 indicated a strong correlation of endoglin
expression in omentum metastatic tumour and
endoglin expression in primary tumour of ovarian
cancer (Table 4).
Table 4. Correlation of Endoglin Expression in Primary
Tumor and Endoglin Expression in Omentum Metastatic
Tumor of Epithelial Ovarian Cancer
Primary Endoglin
Endoglin
Omentum
rs = 0.771
p = 0.000
DISCUSSION
The study showed a significant correlation (strong
category) of endoglin expression in omentum
metastatic tumour and endoglin expression in the
primary tumour of epithelial ovarian cancer.
Statistically, this result showed no significant
correlation between endoglin expression and
clinical stage of epithelial ovarian cancer. Similar
result was reported by Zhai (2011) and Satya et al.
(2016), as well as Annika et al. (2011), concluded
that regardless the cell type, endoglin expression
was not correlated to tumour stage, FIGO classifi-
cation, or volume of the remaining disease after
surgery. Annika et al. (2011) observed endoglin
expression in serous ovarian cancer by assessing
the efusion fluid and the primary tumour. They
found a stronger endoglin expression in patients
with recurrent disease, both in the efusion fluid
and in the primary tumour.9-11
Although there was no statistical correlation of
endoglin expression and clinical stage, the data
showed a linear tendency indicating that positive
endoglin expression was found dominant in the
late stage. Of 37 cases of late-stage ovarian cancer,
31 expressed positive endoglin.
Endoglin expression in primary tumour of
ovarian cancer is not statistically significant at
various level of cells differentiation. The result is
in accordance with the result of Zhai (2011),
Nikiteas et al. (2007), and Satya et al. (2016), which
found that there was no correlation of endoglin
expression and the differentiation level. Previous
study showed that endoglin involved more in
tumour progressivity, proven by its presence as
cell differentiation marker in ovarian cancer.
Previous studies did not specifically state cell
differentiation type. Endoglin (CD105) is a part of
Transforming Growth Factor (TGF)- complex
receptor, a pleiotropic cytokine which involved
in cellular proliferation, differentiation, and
migration.6,10,11
In this study, we did not find any significant
statistical difference of endoglin expression and
the histopathology of epithelial ovarian cancer.
Similar result was found by Nikiteas et al. (2007),
which showed no correlation between endoglin
expression and the histopathology type of cancer.
Data showed that positive endoglin expression was
higher in serous type (52.7%) than in mucinous
type (48.9%).6
From the statistical test, this study indicated a
significant correlation of endoglin expression in
omentum metastatic tumour and the clinical stage
of epithelial ovarian cancer. Endoglin is suggested
as a progressivity marker of various solid tumours
and their metastases by many researchers. This is
different with the study result of Annika et al.
(2011), which concluded that, regardless of the cell
type, endoglin expression is not correlated to the
staging of the tumour, FIGO classification, or the
volume of the remaining disease after surgery.
According to Annika et al. (2011), endoglin
expression in solid metastases is higher than that
in efusion. Similarly, a non-significant tendency
indicated that there is a higher expression in
a primary tumour than in efusion. There is no
significant difference in endoglin staining of the
solid metastatic tumour and primary tumour.
The latter is consistent with our finding which
indicated that there is no significant difference in
endoglin staining of the solid metastatic tumour
and primary tumour. However, we can not confirm
the previous statement since we did not assess
endoglin expression in the efusion fluid of
ovarian cancer.9
In this study, we did not find a significant
statistical correlation of endoglin expression and
histopathology type of epithelial ovarian cancer.
The data showed that positive endoglin expression
was the slightly higher mucinous type (51.4%)
compared to serous type (48.6%). Theoretically,
serous type of epithelial ovarian cancer was found
more frequently. The study of McCluggage (2011)
found that serous adenocarcinoma is the most
Vol 6, No 2
April 2018 Endoglin expression in ephithelial ovarian cancer  127
frequent type of epithelial ovarian cancer, and
most serous type epithelial ovarian cancer was
found in late stage (III & IV). This finding is
consistent with the result of our study, where we
found 29 (51.8%) cases of serous type epithelial
ovarian cancer, and most cases are late-stage
ovarian cancer (67.8%).12
This study showed no significant correlation
between endoglin expression increase and the
clinical stage,  differentiation level,  and
histopathology type of epithelial ovarian cancer
primary tumour. However, there was a significant
correlation of endoglin expression increase of
omentum metastatic tumour and the clinical stage
as well as differentiation level of epithelial ovarian
cancer, but there was no significant correlation
of endoglin expression increase of omentum
metastatic tumour and histopathology type
of epithelial ovarian cancer.
One of some possibilities that may appear is the
presence of angiogenic factor molecular hetero-
geneity of ovarian cancer. That might be caused by
the mutation of ALK-1 and ALK-5 proteins which
then suppress/influence endoglin expression,
both in protein level and mRNA level.3
ALK-1 or activin receptor-like kinase 1 is an
enzyme that is encoded by ACVRL1 gene which
is a receptor in TGF- signaling pathway. While
ALK-5 is a specific receptor enzyme for TGF-1.
Mutation and deletion of ALK-1 and ALK-5 are
frequently found in various cancers of human.
There was a significant correlation between
endoglin expression in primary tumours and
endoglin expression in omentum metastatic
tumour of ovarian cancer. The correlation of
endoglin expression in omentum metastatic
tumour and endoglin expression in primary
tumours was considered as a strong correlation.
The increase of endoglin (CD105) expression
might be detected in microvascular endothelial
cells and in vascular endothelial cells of tissues
with active ongoing angiogenesis, such as tissues
that are in their regeneration process as well as
tumour and its metastases or inflammation. The
result of endoglin (CD105) staining showed more
evident stain in the area with active angiogenesis,
including tumour borders, metastases tumour,
while less evident stain was seen in the central
area of the tumour, and no stain was seen in
normal tissues around a tumour.
 This result is consistent with the results of
previous studies which stated that measuring
endoglin expression by assessing microvascular
density is a proper prognostic indicator; the study
found that the density of endoglin-positive vascular
is associated with metastases of various solid
tumours.3
High level of endoglin expression was associated
with ovarian cancer growth and metastatic
tumour. In tumour pathogenesis, endoglin plays
some big roles, such as inducing tumour
proliferation, invasion, and metastases. Metastases
includes some gradual steps of malignant cells that
spread from the primary tumour to other distant
organs. The recruitment of endothelial cells and
neovascularization play an important role in
tumour progression and metastases. Important
events of metastases including the ability of
tumour to survive in circulation and to invade
other tissues, initiate and maintain the growth, and
form a proangiogenic micrometastases in the
tissue, then eventually form a vascularization for
the macrometastases tumour.
CONCLUSION AND RECOMMENDATION
The investigators concluded that endoglin
expression in ovarian cancer primary tumour is not
correlated to clinical stage, differentiation level,
and histopathology of epithelial ovarian cancer.
Endoglin expression in ovarian cancer metastatic
tumour to omentum is correlated with clinical
stage and differentiation level of ovarian cancer.
Endoglin expression in ovarian cancer metastatic
tumour to omentum is not correlated to histo-
pathological of epithelial ovarian cancer. There is
a strong correlation between endoglin expression
in omentum metastatic tumour and endoglin
expression in primary tumor of ovarian cancer.
And endoglin is one of the pro angiogenic and pro
metastases factors. Further studies are needed,
considering the role of endoglin in therapeutic
target of ovarian cancer has not been reported
considerably. However, endoglin expression is a
proper prognostic marker and a promising
therapeutic target of antiangiogenesis process and
anti-tumor; thus, further studies are needed.
Deeper analyses are needed to explain the
molecular mechanism of other angiogenic factors
in ovarian cancer progressivity.
Indones J
128  Jumsa et al Obstet Gynecol
REFERENCES
1. Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Brad-
shaw KD, Cunningham FG. Williams Gynecology. 23rd ed.,
McGraw Hill companies, inc. 2008: 1432.
2. Berek JS & Natarajan S. Ovarian and Fallopian Tube Cancer.
In Berek JS (ed.) Berek & Novak’s Gynecology. Lippincott
Williams & Wilkins. 2007: 1186.
3. Perez-Gomez E, Castillo GD, Santibanez JF, Lopez-Novoa JM,
Bernabeu C, Quintanilla M. The Role of the TGF- Corecep-
tor Endoglin in Cancer. Scient World J. 2010; 10: 2367-84.
4. Dallas NA, Samuel S, XIA L. Endoglin. (CD105): A Marker of
Tumor Vasculature and Potential Target for Therapy. Clin
Cancer Res. 2008; 14: 1931-7.
5. Manuaba F, Nusratuddin A, Biran A, Yusuf I. An Observa-
tional Study To Assess The Value Of Serum Endoglin When
Combined With Symptoms Of Dysmenorrhea And Infertility
In The Diagnosis Of Patients Suspected Of Having
Endometriosis. Departement of Obstetrics and Gynecology,
Universitas Hasanuddin. 2010: 6.
6. Nikiteas NI, Tzanakis N, Theodoropoulos G, Atsaves V,
Christoni Z, Karakitsos P, Lazaris AC, Papachristodoulou A,
Klonaris C, Gazouli M. Vascular endothelial growth factor
and endoglin (CD-105) in gastric cancer. Gastric Cancer,
2007; 10: 12-7.
7. El-Gohary Y, Silverman J, Olson P, Liu Y, Cohen J, Miller R,
Saad R. Endoglin (CD105) and Vascular Endothelial Growth
Factor as Prognostic Markers in Prostatic Adenocarcinoma.
Am J Clin Pathol, 2007; 127: 572-9.
8. Angela J, Nowsheen S, Steg A, Shah M, Katre A, Dobbin Z,
Han H, Berestein G, Sood A, Conner M, Yang E, Landen E.
Endoglin (CD105) contributes to platinum resistance and is
a target for tumor-specific therapy in epithelial ovarian can-
cer. Clin Cancer Res, 2013; 19(1): 170-82.
9. Annika J, Stavnes H, Kaern J, Berner A, Staff A, Davidson B.
Endoglin (CD105) expression in ovarian serous carcinoma
effusions is related to chemotherapy status. Tumor Biol,
2011; 32: 589-96.
10. Zhai Z. The Role Of Endoglin In Angiogenesis And Its Po-
tential As An Anti-Angiogenic Therapeutic Target. Doctor of
Philosophy Newcastle University. 2011: 115-48.
11. Satya A, Rauf S, Sunarno I. Hubungan ekspresi vascular en-
dothelial growth factor dan endoglin dengan stadium, dera-
jat diferensiasi dan tipe histopatologi kanker ovarium tipe
epitelial. Bagian Obstetri dan Ginekologi Fakultas Kedok-
teran Universitas Hasanuddin. 2016; 5-6.
12. McCluggage G. Ovarian Epithelial Tumours: Morphologic
Types, New Developments and Pathogenesis. Belfast: Royal
Group of Hospitals. 2011: 15-9.
Vol 6, No 2
April 2018 Endoglin expression in ephithelial ovarian cancer  129
